Qiagen recently reported quarterly results that exceeded expectations, driven by strong organic sales growth in its diagnostics solutions.
UBS has maintained a "Neutral" rating on the company and set a target price of 50 euros. However, analyst Dan Leonard expressed concerns about Qiagen's ability to achieve growth rates comparable to its competitors, citing a slower recovery in the biopharma sector.